Avantax Advisory Services’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $858K | Sell |
96,901
-125,832
| -56% | -$1.11M | ﹤0.01% | 1257 |
|
|
2025
Q1 | $1.74M | Buy |
222,733
+56,277
| +34% | +$441K | 0.01% | 805 |
|
|
2024
Q4 | $1.75M | Buy |
166,456
+79,248
| +91% | +$833K | 0.01% | 774 |
|
|
2024
Q3 | $1.14M | Buy |
87,208
+3,416
| +4% | +$44.8K | 0.01% | 954 |
|
|
2024
Q2 | $1.18M | Buy |
83,792
+28,036
| +50% | +$394K | 0.01% | 900 |
|
|
2024
Q1 | $942K | Buy |
55,756
+30,856
| +124% | +$521K | 0.01% | 775 |
|
|
2023
Q4 | $352K | Buy |
24,900
+900
| +4% | +$12.7K | ﹤0.01% | 1152 |
|
|
2023
Q3 | $247K | Hold |
24,000
| – | – | ﹤0.01% | 1303 |
|
|
2023
Q2 | $396K | Buy |
24,000
+2,500
| +12% | +$41.2K | ﹤0.01% | 1040 |
|
|
2023
Q1 | $197K | Buy |
21,500
+9,000
| +72% | +$82.4K | ﹤0.01% | 1383 |
|
|
2022
Q4 | $89.5K | Sell |
12,500
-1,000
| -7% | -$7.16K | ﹤0.01% | 1371 |
|
|
2022
Q3 | $68K | Hold |
13,500
| – | – | ﹤0.01% | 1287 |
|
|
2022
Q2 | $33K | Sell |
13,500
-500
| -4% | -$1.22K | ﹤0.01% | 1284 |
|
|
2022
Q1 | $96K | Sell |
14,000
-11,000
| -44% | -$75.4K | ﹤0.01% | 1240 |
|
|
2021
Q4 | $202K | Hold |
25,000
| – | – | ﹤0.01% | 1166 |
|
|
2021
Q3 | $248K | Buy |
25,000
+2,000
| +9% | +$19.8K | ﹤0.01% | 1006 |
|
|
2021
Q2 | $154K | Buy |
23,000
+3,500
| +18% | +$23.4K | ﹤0.01% | 1101 |
|
|
2021
Q1 | $177K | Buy |
+19,500
| New | +$177K | ﹤0.01% | 973 |
|